Replies to post #219178 on Avid Bioservices Inc (CDMO)

[biopharm]

Recent studies describe a heterogeneous population of cells of the myeloid lineage, termed myeloid derived suppressor cells (MDSC), which are observed with increased prevalence in the peripheral blood and tumor microenvironment of cancer patients, including pancreatic cancer. Accumulation of MDSC in the peripheral circulation has been related to extent of disease, and correlates with stage. MDSC have primarily been implicated in promoting tumor growth by suppressing antitumor immunity. There is also compelling evidence MDSC are also involved in angiogenesis and metastatic spread. Two main subsets of MDSC have been identified in cancer patients: a monocytic subset, characterized by expression of CD14, and a granulocytic subset characterized by expression of CD15. Both subsets of MDSC actively suppress host immunity through a variety of mechanisms including production of reactive oxygen species and arginase. Just as in humans, accumulation of monocytic and granulocytic MDSC has been noted in the bone marrow, spleen, peripheral circulation, and tumors of tumor bearing mice. Successful targeting of MDSC in mice is associated with improved immune responses, delayed tumor growth, improved survival, and increased efficacy of vaccine therapy.

So who states they can reduce those MDSC's ?? Well here is some news for you, the ones reminding you of the pps at $1.30 will not dare bring up that Peregrine Pharmaceuticals has already discovered long ago that PS Targeting reduces those MDSC's and it has been scientifically proven. Oh... maybe that is one of the reasons that Memorial Sloan Kettering (the #1 cancer hospital) has jumped all over the PS Targeting and decided they must collaborate with Peregrine and and continue to see how Bavituximab can provide that optimal immune response. This will jump-start an entire new set of immuno-therapy trials arising out of MSK.

--------------------

Newly Presented Data Shows That Peregrine Pharmaceuticals' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity of Immune Checkpoint Inhibitors PD-1 and CTLA-4 in Models of Breast Cancer and Melanoma

Feb 9, 2015

...
..
PS-Targeting Antibodies Block Tumor Suppression of Immune System Allowing Development of Robust Immune Responses Resulting in Statistically Significant Improvement in Anti-Tumor Activity; Specific Effects Seen in Decreased Levels of MDSCs and Other Immunosuppressive Lymphocytes and Increases in Tumor Fighting Immune Cells

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=895363